Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 11/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043231 | 0.90 | GSK3B (0.50) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL13304831 | 0.89 | CDK2 (0.58) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14418865 | 0.83 | GSK3B (0.41) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14581371 | 0.82 | GSK3B (0.46) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12954361 | 0.80 | GSK3B (0.42) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14043168 | 0.80 | KMT2A (0.46) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL12953809 | 0.80 | RAB9A (0.43) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14301781 | 0.80 | RET (0.46) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL13305293 | 0.80 | GSK3B (0.50) | GSK3BMEN1KMT2ANPC1RAB9A | |
| SCHEMBL14050875 | 0.79 | GSK3B (0.43) | GSK3BMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | GSK3B 695/4885MEN1 3219/4885KMT2A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.